发布求助
文献互助 智能选刊 最新文献

Profiles of drug substances, excipients, and related methodology最新文献

筛选
英文 中文
Ponatinib: A comprehensive drug profile. Ponatinib：全面的药物简介。
Profiles of drug substances, excipients, and related methodology Pub Date : 2024-01-01 Epub Date: 2024-01-25 DOI: 10.1016/bs.podrm.2023.11.005
Mohamed W Attwa, Hamad M Alkahtani, Adel S El-Azab, Alaa A-M Abdel-Aziz, Ali S Abdelhameed, Adnan A Kadi, Sawsan Bushra Hassan, Dalia W Zeidan, Ahmed H Bakheit
{"title":"Ponatinib: A comprehensive drug profile.","authors":"Mohamed W Attwa, Hamad M Alkahtani, Adel S El-Azab, Alaa A-M Abdel-Aziz, Ali S Abdelhameed, Adnan A Kadi, Sawsan Bushra Hassan, Dalia W Zeidan, Ahmed H Bakheit","doi":"10.1016/bs.podrm.2023.11.005","DOIUrl":"10.1016/bs.podrm.2023.11.005","url":null,"abstract":"<p><p>Ponatinib is a prescription medication used to treat a rare form of blood cancer called Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) and chronic myeloid leukemia (CML) that is resistant to other treatments. It belongs to a class of drugs called tyrosine kinase inhibitors, which work by blocking abnormal proteins that promote the growth of cancer cells. In this chapter, the synthesis methods and physicochemical properties of ponatinib were reviewed, besides the characterization of the ponatinib structure using different techniques such as elemental analysis, IR, UV, (<sup>1</sup>H and <sup>13</sup>C) NMR, MS, and XRD. Furthermore, the compendial method for analysis of ponatinib was not found, while the literature review of a non-compendial method for analysis of ponatinib, such as spectroscopic, chromatographic, and immunoassay methods, was covered. Moreover, pharmacology and biochemistry were surveyed in the pharmacokinetic and pharmacodynamic studies.</p>","PeriodicalId":20802,"journal":{"name":"Profiles of drug substances, excipients, and related methodology","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139997297","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Deferasirox: A comprehensive drug profile. 地拉罗司：全面的药物简介。
Profiles of drug substances, excipients, and related methodology Pub Date : 2024-01-01 Epub Date: 2024-01-22 DOI: 10.1016/bs.podrm.2023.11.001
Mohamed Fawzi Kabil, Maha Nasr
{"title":"Deferasirox: A comprehensive drug profile.","authors":"Mohamed Fawzi Kabil, Maha Nasr","doi":"10.1016/bs.podrm.2023.11.001","DOIUrl":"10.1016/bs.podrm.2023.11.001","url":null,"abstract":"<p><p>Deferasirox is an iron-chelating drug developed by Novartis company for treatment of diseases accompanied by chronic iron overload; such as β-thalassemia or sickle cell diseases. Owing to its advantages such as high affinity, specificity and wide therapeutic window, it is considered as first line treatment. The current chapter describes the physicochemical characteristics, mode of action, pharmacokinetics, therapeutic applications and synthetic methods for deferasirox. Moreover, it includes Fourier transform infrared spectrometry (FTIR) and nuclear magnetic resonance spectroscopy (NMR) analysis for its functional groups. In addition, the selected analytical methods are summarized to aid the analysts in their routine analysis of deferasirox.</p>","PeriodicalId":20802,"journal":{"name":"Profiles of drug substances, excipients, and related methodology","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139997295","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Regorafenib: A comprehensive drug profile. 瑞戈非尼：全面的药物简介。
Profiles of drug substances, excipients, and related methodology Pub Date : 2024-01-01 Epub Date: 2023-12-07 DOI: 10.1016/bs.podrm.2023.11.004
Ahmed A Abdelgalil, Hamad M Alkahtani
{"title":"Regorafenib: A comprehensive drug profile.","authors":"Ahmed A Abdelgalil, Hamad M Alkahtani","doi":"10.1016/bs.podrm.2023.11.004","DOIUrl":"10.1016/bs.podrm.2023.11.004","url":null,"abstract":"<p><p>Regorafenib is a small molecule tyrosine kinase inhibitor administered orally drug, act by inhibiting the activity of the VEGF receptors. It is used for the treatment of patients with metastatic colorectal cancer (CRC), advanced gastrointestinal stromal tumors, and hepatocellular carcinoma. This comprehensive profile on regorafenib includes an original data as well as data collected from the literature on Profiles of Methods of Drug Synthesis, different Physical Drug Profiles, Drug Analytical methods and Pharmacological profile (ADME). This chapter is divided into five main sections: General Description of the drug, Physical Characteristics, Methods of Preparation, Methods of Analysis, Pharmacology and List of References. These main sections are further divided to many sub-titles to cover most aspect of the drug in the light of the available literature. Among these sub-titles are the formulae, Elemental Analysis, physical characteristics which include constant of ionization, solubility, X-ray powder diffraction pattern, TGA, thermal conduct and spectroscopic and stability. Additionally, analytical techniques including Electrochemical, Spectrophotometric and chromatographic methods, ADME profiles and pharmacological effects were also discussed. Furthermore, methods and schemes are outlined for the preparation of the drug substance.</p>","PeriodicalId":20802,"journal":{"name":"Profiles of drug substances, excipients, and related methodology","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139997298","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Avanafil: A comprehensive drug profile. 阿伐那非：药物综合概况。
Profiles of drug substances, excipients, and related methodology Pub Date : 2024-01-01 Epub Date: 2023-12-13 DOI: 10.1016/bs.podrm.2023.11.006
Abdulrahman A Al-Majed, Amer AlKhairallah, Mohamed W Attwa, Hamad M Alkahtani, Adel S El-Azab, Alaa A-M Abdel-Aziz, Ayman Alkhider, Sawsan Bushra Hassan, Ahmed H Bakheit
{"title":"Avanafil: A comprehensive drug profile.","authors":"Abdulrahman A Al-Majed, Amer AlKhairallah, Mohamed W Attwa, Hamad M Alkahtani, Adel S El-Azab, Alaa A-M Abdel-Aziz, Ayman Alkhider, Sawsan Bushra Hassan, Ahmed H Bakheit","doi":"10.1016/bs.podrm.2023.11.006","DOIUrl":"10.1016/bs.podrm.2023.11.006","url":null,"abstract":"<p><p>Avanafil is an oral medication used to treat erectile dysfunction (ED). As a phosphodiesterase type 5 (PDE5) inhibitor, it functions by inhibiting the PDE5 enzyme, which ultimately results in increased levels of cyclic guanosine monophosphate (cGMP) and improved blood flow to the penis. Approved by the FDA in 2012, avanafil is recognised for its rapid onset of action, short half-life, and favourable side-effects profile. While it has been explored for other potential therapeutic applications, its current approved use is limited to ED and should be used as prescribed by a medical professional. This chapter provides a comprehensive review of avanafil, encompassing its nomenclature, physicochemical properties, methods of preparation, and identification. Various techniques for analysing avanafil, such as electrochemical analysis, spectrophotometric, spectrofluorimetric, and chromatographic techniques, are discussed. The pharmacology of avanafil, including its pharmacokinetics and pharmacodynamics, is also examined.</p>","PeriodicalId":20802,"journal":{"name":"Profiles of drug substances, excipients, and related methodology","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139997294","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Duvelisib: A comprehensive profile. 杜维力：综合概况。
Profiles of drug substances, excipients, and related methodology Pub Date : 2024-01-01 Epub Date: 2023-12-07 DOI: 10.1016/bs.podrm.2023.11.002
Haya I Aljohar, Ebtehal Al-Abdullah, Nourah Z Alzoman, Hany W Darwish, Ibrahim A Darwish
{"title":"Duvelisib: A comprehensive profile.","authors":"Haya I Aljohar, Ebtehal Al-Abdullah, Nourah Z Alzoman, Hany W Darwish, Ibrahim A Darwish","doi":"10.1016/bs.podrm.2023.11.002","DOIUrl":"10.1016/bs.podrm.2023.11.002","url":null,"abstract":"<p><p>Duvelisib (DUV) is chemically named as (S)-3-(1-((9H-Purin-6-yl)amino)ethyl)-8-chloro-2-phenylisoquinolin-1(2H)-one. It is a novel drug with a small molecular weight and characterized by dual phosphoinositide-3-kinase (PI3K)- and PI3K-inhibitory activity. The Food and Drug Administration (FDA) recently approved DUV for the management of small lymphocytic lymphoma (SLL) and relapsed or refractory chronic lymphocytic leukemia (CLL) in adult patients. DUV is marketed under the brand name of Copiktra® (Verastem, Inc., Needham, MA, USA). This chapter provides a critical extensive review of the literature, the description of DUV in terms of its names, formulae, elemental composition, appearance, and use in the treatment of CLL, SLL, and follicular lymphoma. The chapter also describes the methods for preparation of DUV, its physical-chemical properties, analytical methods for its determination, pharmacological properties, and dosing information.</p>","PeriodicalId":20802,"journal":{"name":"Profiles of drug substances, excipients, and related methodology","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139997296","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Regulation and standardization of herbal drugs: Current status, limitation, challenge's and future prospective. 草药的监管和标准化：现状、局限性、挑战和未来展望。
Profiles of drug substances, excipients, and related methodology Pub Date : 2024-01-01 Epub Date: 2023-12-12 DOI: 10.1016/bs.podrm.2023.11.003
Gunawan Indrayanto
{"title":"Regulation and standardization of herbal drugs: Current status, limitation, challenge's and future prospective.","authors":"Gunawan Indrayanto","doi":"10.1016/bs.podrm.2023.11.003","DOIUrl":"10.1016/bs.podrm.2023.11.003","url":null,"abstract":"<p><p>Herbal drugs (HD) or traditional drugs have been used worldwide for centuries, especially in the developing countries. Global market of HD reaches billion of USD annually and increases every year. For ensuring the safety and efficacy of HD, the Drug Agency/Authority issues regulations for the registration & application of new HD, their manufacturing processes, controlling and monitoring in the market. The efficacy and safety of HD depend on their whole chemical contents. Quality assessment of HD should be performed using standardization methods according to the current Pharmacopoeias or Materia Medica. Unfortunately, the official methods of the compendia cannot be applied for evaluation of mixed herbs and their preparations.; HD's producers should develop, validate, and standardize the method for the quality assessment of their own specific products. Therefore, assuring the safety and efficacy of HD remains a challenging task due to the complex nature of HD, that typically consist of many constituents of herbs/extracts whose quality may vary among different sources of materials. This present review will describe, compare, and discuss the regulations and standardization methods of HD from US, EU countries, Japan, Taiwan, Hong Kong and Indonesia. The official standardization methods of HD, their current criteria, limitations, challenge and future prospective will be described and discussed. Official methods for quality assessment of HD should be state of the art, fast, low-cost, accurate and precise, and could be used for evaluation of all kinds of HD.</p>","PeriodicalId":20802,"journal":{"name":"Profiles of drug substances, excipients, and related methodology","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139997299","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Remdesivir
Profiles of drug substances, excipients, and related methodology Pub Date : 2023-02-01 DOI: 10.1007/s40278-023-34554-z
Ahmed H H Bakheit, H. Darwish, I. Darwish, Ahmed I. Al-Ghusn
{"title":"Remdesivir","authors":"Ahmed H H Bakheit, H. Darwish, I. Darwish, Ahmed I. Al-Ghusn","doi":"10.1007/s40278-023-34554-z","DOIUrl":"https://doi.org/10.1007/s40278-023-34554-z","url":null,"abstract":"","PeriodicalId":20802,"journal":{"name":"Profiles of drug substances, excipients, and related methodology","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2023-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"79027077","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Preface. 前言。
Profiles of drug substances, excipients, and related methodology Pub Date : 2023-01-01 DOI: 10.1016/S1871-5125(23)00009-2
Abdulrahman A Al-Majed
{"title":"Preface.","authors":"Abdulrahman A Al-Majed","doi":"10.1016/S1871-5125(23)00009-2","DOIUrl":"https://doi.org/10.1016/S1871-5125(23)00009-2","url":null,"abstract":"","PeriodicalId":20802,"journal":{"name":"Profiles of drug substances, excipients, and related methodology","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9361385","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Crizotinib: A comprehensive profile. 克唑替尼:全面概况。
Profiles of drug substances, excipients, and related methodology Pub Date : 2023-01-01 DOI: 10.1016/bs.podrm.2022.11.002
Ahmed A Abdelgalil, Hamad M Alkahtani
{"title":"Crizotinib: A comprehensive profile.","authors":"Ahmed A Abdelgalil,&nbsp;Hamad M Alkahtani","doi":"10.1016/bs.podrm.2022.11.002","DOIUrl":"https://doi.org/10.1016/bs.podrm.2022.11.002","url":null,"abstract":"<p><p>Crizotinib, approved in 2011, was the first approved inhibitor targeting anaplastic lymphoma kinase (ALK) It used for treatment of the patients with metastatic non-small cell lung cancer (NSCLC) that is anaplastic lymphoma kinase (ALK) positive. This chapter provides a complete review of crizotinib including nomenclature, physiochemical properties, methods of preparation, identification techniques and various qualitative and quantitative analytical techniques as well as pharmacology of crizotinib. In addition, the chapter also includes review of several methods for separation of crizotinib using chromatographic techniques.</p>","PeriodicalId":20802,"journal":{"name":"Profiles of drug substances, excipients, and related methodology","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9315710","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Lapatinib: A comprehensive profile. 拉帕替尼:全面的概况。
Profiles of drug substances, excipients, and related methodology Pub Date : 2023-01-01 DOI: 10.1016/bs.podrm.2022.11.005
Ahmed A Abdelgalil, Hamad M Alkahtani
{"title":"Lapatinib: A comprehensive profile.","authors":"Ahmed A Abdelgalil,&nbsp;Hamad M Alkahtani","doi":"10.1016/bs.podrm.2022.11.005","DOIUrl":"https://doi.org/10.1016/bs.podrm.2022.11.005","url":null,"abstract":"<p><p>Lapatinib is an anticancer used for treatment of the patients with advanced metastatic breast cancer in conjunction with the chemotherapy drug capecitabine or with letrozole for the treatment of postmenopausal women with hormone receptor-positive metastatic breast cancer. This comprehensive profile of Lapatinib gives more detailed information about the description, formulae, Elemental Analysis, Uses and application. Furthermore, methods and schemes are outlined for the preparation of the drug substance. The physical properties of the medication include constant of ionization, solubility, X-ray powder diffraction pattern, differential scanning calorimetry, thermal conduct and spectroscopic studies are investigated. The methods employed in bulk medicines and/or in pharmaceutical formulations to analyze the drug substance include spectrophotometric, electrochemical and the chromatographic methods are indicated. Other studies on this drug substance include drug stability, pharmaceutical applications, mechanism of action, pharmacodynamics, and a dosing information are also reviewed.</p>","PeriodicalId":20802,"journal":{"name":"Profiles of drug substances, excipients, and related methodology","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9315709","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
下一页 尾页
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整，为了账户安全，请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们：info@booksci.cn Book学术提供免费学术资源搜索服务，方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号：481959085
Book学术官方微信